NEW YORK, Sept. 20, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the “Class Period”), of the important September 27, 2024 lead plaintiff deadline. SO WHAT: If you purchased Lifecore securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ar ...

NEW YORK, Sept. 17, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the "Class Period"), of the important September 27, 2024 lead plaintiff deadline.So What: If you purchased Lifecore securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.W ...

文章核心观点 - 公司Lifecore Biomedical, Inc.在2020年10月7日至2024年3月19日期间存在财务报告不准确的问题,需要进行重述 [1][4] - 公司内部财务报告控制存在缺陷,导致财务数据存在错误 [4] - 公司的整改措施未能有效解决上述问题,影响了公司按时向证券交易委员会提交定期报告 [4] - 由于上述问题,公司的财务状况和前景被过度夸大了 [4] 根据相关目录分别进行总结 公司概况 - Lifecore Biomedical, Inc.是一家上市公司,股票代码为LFCR [1] 诉讼情况 - 罗森律师事务所代表投资者对Lifecore Biomedical提起集体诉讼 [1][2] - 投资者可以在2024年9月27日之前加入该集体诉讼 [2] - 罗森律师事务所在证券集体诉讼方面有丰富的经验和良好的业绩记录 [3] 诉讼指控 - 公司在上述期间做出了虚假或误导性陈述,或未能披露以下信息 [4]: 1) 公司内部财务报告控制存在缺陷 [4] 2) 由于上述缺陷,公司发布了多份需要重述的不准确财务报表 [4] 3) 公司的整改措施未能有效解决上述问题 [4] 4) 上述问题影响了公司按时向证券交易委员会提交定期报告 [4] 5) 由于上述问题,公司的财务状况和前景被过度夸大了 [4]

NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the “Class Period”), of the important September 27, 2024 lead plaintiff deadline. SO WHAT: If you purchased Lifecore securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ar ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lifecore To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Lifecore between October 7, 2020 and March 19, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 13, 2024 (GLOBE ...

CHASKA, Minn., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that Paul Josephs, the Company’s president and chief executive officer, and Ryan Lake, the Company’s chief financial officer, will be the featured speakers in a fireside chat at the upcoming Craig-Hallum Bioprocessing Conference. The conference will take place virtually on September 19, 2024. ...

SAN DIEGO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Lifecore Biomedical, Inc. (NASDAQ: LFCR) securities between October 7, 2020 and March 19, 2024. Lifecore operates as an integrated contract development and manufacturing organization in the U.S. and internationally. The Company purportedly designs, develops, manufactures, and sells differentiated products for biomateria ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Sept. 09, 2024 (GLOBE NEWSWIRE) --  The Portnoy Law Firm advises Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ: LFCR) investors of a class action representing investors that bought securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"). Lifecore investors have until September 27, 2024 to file a lead plaintiff motion. Investors are encouraged to contact attor ...

CHASKA, Minn., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the Company will participate in the upcoming 17th Annual Barrington Research Virtual Fall Investment Conference. Lifecore management will participate in 1-on-1 investor meetings during the event, which is scheduled to take place virtually on Thursday, September 12, 2024. About Lifecore B ...

财务数据和关键指标变化 - 公司2024财年总收入达1.283亿美元,同比增长24.2% [20] - 2024财年毛利达4,190万美元,毛利率为32.6%,较上年提升5.5个百分点 [22] - 2024财年调整后EBITDA达2,020万美元,同比增长82% [23] 各条业务线数据和关键指标变化 - 透明质酸原料制造业务收入增长17.7% [21] - CDMO业务收入增长26.5%,主要由于新产品商业化、现有客户需求增加、价格上涨以及开发服务项目有所增加 [21] 各个市场数据和关键指标变化 - 无具体披露 公司战略和发展方向及行业竞争 - 公司正在进行全面的运营、流程、能力和设施审查,以提高效率和竞争力 [41][42] - 公司将通过3个关键领域推动增长:最大化基础业务和客户、推进开发管线商业化、积极拓展新项目管线 [43][45][46] - 公司新增5头隔离灌装设备,有利于在粘稠和难处理产品领域的竞争 [46] - 公司正在加大商业团队和营销投入,以提高市场知名度 [47][48] 管理层对经营环境和未来前景的评论 - 公司2025财年收入指引为1.265-1.3亿美元,基本持平,受到主要客户库存调整、新产品商业化推迟以及一个小客户内部化生产的影响 [26][27][28] - 2025财年调整后EBITDA指引为1,900-2,100万美元,预计毛利率将下降225-275个基点,但运营费用将下降200-250个基点 [30][31][32] - 公司有信心未来收入和利润率将有所改善,将在11月的投资者日上分享更多长期战略信息 [29] 其他重要信息 - 公司已完成所有历史财务报表的重述,并恢复了所有SEC报告的最新状态 [12][13][40] - 公司实施了9%的裁员,预计可带来470万美元的年度薪酬和福利成本节约 [32] - 2025财年预计资本支出将降至1,000-1,400万美元,主要用于新灌装设备的最终安装和维护 [38] 问答环节重要的提问和回答 问题1 **Michael Petusky 提问** 公司如何弥补主要客户库存调整和一个小客户内部化生产带来的收入损失,实现2025财年的收入指引 [54][55] **Paul Josephs 回答** 公司现有商业收入前景依然强劲,加上新项目带来的贡献,可以弥补上述收入损失,实现2025财年的收入指引 [55][56] 问题2 **Unidentified Analyst 提问** 公司中长期增长前景如何,是否有望实现双位数增长?公司是否有能力支持GLP-1类产品的填充生产 [59][61] **Paul Josephs 回答** 公司对未来前景充满信心,将凭借注射剂市场的增长机会实现持续增长。公司具备生产GLP-1等产品的能力 [60] 问题3 **Unidentified Analyst 提问** 2025财年EBITDA毛利率预计持平,裁员带来的成本节约如何体现?未来EBITDA增量空间如何 [61][63] **John D. Morberg 回答** 2025财年毛利率下降主要由于商业收入占比提高和折旧成本增加,但裁员带来的运营费用节约可以抵消。未来随着收入规模扩大,公司有望进一步提升EBITDA利润率 [63][64]